Cytokinetics EVP R&D Malik Fady Ibraham disposes of 3,500 common shares for $265,370
Reuters2026/08/18 20:39- Malik Fady Ibraham, EVP Research & Development at Cytokinetics, exercised stock options for 3,500 shares on Aug. 18, 2026 at USD 7.8.
- Same day sale of 3,500 shares at USD 75.82; direct holdings fell to 153,902 shares.
- Non-Qualified Stock Option (Right to Buy) balance declined to 30,386 options, exercisable through Feb. 27, 2028.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Moody's to Acquire Minority Stake in Philippine Rating Services
Karya Pacific Energy to redeem IDR 149.83 billion debt on Oct. 6, 2026
Bank of America: S&P 500 is forming a bullish flag during consolidation, with a long-term target still above 8,000 points
Bank of America technical analysts remain bullish on the long-term uptrend, believing that the S&P 500 Index is likely to break above 8,000 points, despite a recent series of market and macroeconomic headwinds testing investor confidence.
DEG Impact structures INR 1 billion India local-currency hedge loan with Deutsche Bank
Crypto prices
More
